Literature DB >> 23701395

Haemangioma: clinical course, complications and management.

M Luu1, I J Frieden.   

Abstract

Despite their high incidence, most infantile haemangiomas (IH) do not require treatment as they regress spontaneously and most do not leave significant sequelae. For the subset of haemangiomas that require treatment, indications for intervention can be divided into three main categories: ulceration, disfigurement and impairment of function or vital structures. In addition, certain IH have a risk of associated structural anomalies. Given the wide heterogeneity of haemangiomas, deciding which haemangiomas need intervention and when to intervene requires a detailed knowledge of natural history and clinical indicators of increased risk.
© 2013 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23701395     DOI: 10.1111/bjd.12436

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

Review 1.  Educational paper: Pathogenesis of infantile haemangioma, an update 2014 (part I).

Authors:  Sherief R Janmohamed; Gerard C Madern; Peter C J de Laat; Arnold P Oranje
Journal:  Eur J Pediatr       Date:  2014-08-26       Impact factor: 3.183

2.  Retrospective analysis of beta-blocker instituted for treatment of hemangiomas (RABBIT study).

Authors:  Derek H Chu; Leslie Castelo-Soccio; Joy Wan; Joel M Gelfand; Robert E Shaddy; Kara N Shah; Marissa J Perman; James R Treat; Albert C Yan
Journal:  Clin Pediatr (Phila)       Date:  2014-05-21       Impact factor: 1.168

Review 3.  Educational paper: therapy of infantile haemangioma--history and current state (part II).

Authors:  Sherief R Janmohamed; Gerard C Madern; Peter C J de Laat; Arnold P Oranje
Journal:  Eur J Pediatr       Date:  2014-09-03       Impact factor: 3.183

4.  A hydrogel-endothelial cell implant mimics infantile hemangioma: modulation by survivin and the Hippo pathway.

Authors:  Masayuki Tsuneki; Steven Hardee; Michael Michaud; Raffaella Morotti; Erin Lavik; Joseph A Madri
Journal:  Lab Invest       Date:  2015-05-11       Impact factor: 5.662

Review 5.  Treatment of infantile haemangiomas: recommendations of a European expert group.

Authors:  Peter H Hoeger; John I Harper; Eulalia Baselga; Damien Bonnet; Laurence M Boon; Marta Ciofi Degli Atti; Maya El Hachem; Arnold P Oranje; Agneta Troilius Rubin; Lisa Weibel; Christine Léauté-Labrèze
Journal:  Eur J Pediatr       Date:  2015-05-29       Impact factor: 3.183

6.  Wound management of ulcerated haemangioma of infancy - an audit.

Authors:  Zerina Lokmic; Taya Grainger; Nadeeja V Atapattu; Roderic J Phillips; Anthony J Penington
Journal:  Int Wound J       Date:  2017-03-01       Impact factor: 3.315

7.  Propranolol targets the contractility of infantile haemangioma-derived pericytes.

Authors:  D Lee; E Boscolo; J T Durham; J B Mulliken; I M Herman; J Bischoff
Journal:  Br J Dermatol       Date:  2014-08-28       Impact factor: 9.302

8.  Impact of congenital cutaneous hemangiomas on newborn care in the United States.

Authors:  Raghav Tripathi; Rishabh S Mazmudar; Konrad D Knusel; Harib H Ezaldein; Leah T Belazarian; Jeremy S Bordeaux; Jeffrey F Scott
Journal:  Arch Dermatol Res       Date:  2020-10-19       Impact factor: 3.017

9.  The effectiveness of oral propranolol for infantile hemangioma on the head and neck region: A case series.

Authors:  Prasetyanugraheni Kreshanti; Nandya Titania Putri; Valencia Jane Martin; Chaula Luthfia Sukasah
Journal:  Int J Surg Case Rep       Date:  2021-06-19

10.  Sleep behavior of infants with infantile hemangioma treated with propranolol-a cohort study.

Authors:  Martin Theiler; Nicole Knöpfel; Susanne von der Heydt; Agnes Schwieger-Briel; Isabelle Luchsinger; Alexandra Smith; Kristin Kernland-Lang; Regula Waelchli; Kathrin Neuhaus; Malcolm Kohler; Ralph Gnannt; Sarah F Schoch; Lisa Weibel; Salome Kurth
Journal:  Eur J Pediatr       Date:  2021-06-18       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.